Search Results - "LEHNERT, Manfred"

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors by Patnaik, Amita, Kang, S Peter, Rasco, Drew, Papadopoulos, Kyriakos P, Elassaiss-Schaap, Jeroen, Beeram, Muralidhar, Drengler, Ronald, Chen, Cong, Smith, Lon, Espino, Guillermo, Gergich, Kevin, Delgado, Liliana, Daud, Adil, Lindia, Jill A, Li, Xiaoyun Nicole, Pierce, Robert H, Yearley, Jennifer H, Wu, Dianna, Laterza, Omar, Lehnert, Manfred, Iannone, Robert, Tolcher, Anthony W

“…This phase I study evaluated the safety, maximum tolerated dose, antitumor activity, and pharmacokinetics and pharmacodynamics of pembrolizumab in patients…”
Get full text

Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC) by Coombes, Charles, Howell, Sasha J, Krebs, Matthew G, Lord, Simon, Kenny, Laura M, Bahl, Ash, Clack, Glen, Ainscow, Edward, Dickinson, Paul A, Fostea, Raluca, Mansi, Janine, Palmieri, Carlo, Bertelli, Gianflippo, Jeselsohn, Rinath, Mitri, Zahi, Gradishar, William J, Sardesai, Sagar, O'Shaughnessy, Joyce, Ward, Patrick, Chalasani, Pavani, Lehnert, Manfred, Ali, Simak, McIntosh, Stuart

“…Abstract Background: CDK7 inhibition is a promising therapeutic strategy in cancer; acting as a regulator of the cell cycle, transcription and endocrine…”
Get full text

Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC) by Howell, Sacha J, Kenny, Laura M, Lord, Simon, Krebs, Matthew G, Arkenau, Tobias, Baird, Richard, MacPherson, Iain R, Bahl, Ash, Clack, Glen, Ainscow, Edward, Barrett, Anthony GM, Dickinson, Paul A, Fuchter, Matthew J, Lehnert, Manfred, Ali, Simak, McIntosh, Stuart, Coombes, Charles

“…Abstract Background: CDK7 inhibition is a promising therapeutic strategy in cancer. CDK7 is a key kinase, regulating cell division, transcription and nuclear…”
Get full text

Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer by Goh, B C, Lehnert, M, Lim, H L, Ng, A W, Chan, C C, Kong, H L, Lee, S C, Wee, J, Chua, E T, Wong, J E

“…Docetaxel has a response rate of greater than 30% in first-line treatment of Western patients with advanced non-small cell lung cancer (NSCLC). The goal of…”
Get more information

Intermittent exposure to doxorubicin in vitro selects for multifactorial non‐P‐glycoprotein‐associated multidrug resistance in RPMI 8226 human myeloma cells by Wyler, Beat, Shao, Ying, Schneider, Erasmus, Cianfriglia, Maurizio, Scheper, Rik J., Frey, Beat M., Gieseler, Frank, Schmid, Luzius, Twentyman, Peter R., Lehnert, Manfred

“…The purpose of the present study was to evaluate whether intermittent exposure to a constant dose of doxorubicin selects for multidrug resistance (MDR) in RPMI…”
Get full text

Enzastaurin – From bench to bedside, and back by Lehnert, Manfred

Get full text

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer by Lazar, Vladimir, Rubin, Eitan, Depil, Stephane, Pawitan, Yudi, Martini, Jean-François, Gomez-Navarro, Jesus, Yver, Antoine, Kan, Zhengyin, Dry, Jonathan R, Kehren, Jeanne, Validire, Pierre, Rodon, Jordi, Vielh, Philippe, Ducreux, Michel, Galbraith, Susan, Lehnert, Manfred, Onn, Amir, Berger, Raanan, Pierotti, Marco A, Porgador, Angel, Pramesh, C S, Ye, Ding-wei, Carvalho, Andre L, Batist, Gerald, Le Chevalier, Thierry, Morice, Philippe, Besse, Benjamin, Vassal, Gilles, Mortlock, Andrew, Hansson, Johan, Berindan-Neagoe, Ioana, Dann, Robert, Haspel, Joel, Irimie, Alexandru, Laderman, Steve, Nechushtan, Hovav, Al Omari, Amal S, Haywood, Trent, Bresson, Catherine, Soo, Khee Chee, Osman, Iman, Mata, Hilario, Lee, Jack J, Jhaveri, Komal, Meurice, Guillaume, Palmer, Gary, Lacroix, Ludovic, Koscielny, Serge, Eterovic, Karina Agda, Blay, Jean-Yves, Buller, Richard, Eggermont, Alexander, Schilsky, Richard L, Mendelsohn, John, Soria, Jean-Charles, Rothenberg, Mace, Scoazec, Jean-Yves, Hong, Waun Ki, Kurzrock, Razelle

“…Non-small cell lung cancer (NSCLC) is a leading cause of death worldwide. Targeted monotherapies produce high regression rates, albeit for limited patient…”
Get full text

Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors by Patnaik, Amita, Kang, Soonmo Peter, Tolcher, Anthony W., Rasco, Drew Warren, Papadopoulos, Kyriakos P., Beeram, Muralidhar, Drengler, Ronald, Chen, Cong, Smith, Lon, Perez, Crystal, Gergich, Kevin, Lehnert, Manfred

“…Abstract only 2512 Background: Programmed death-1 (PD-1) is an inhibitory T-cell coreceptor that may lead to suppression of antitumor immunity. MK-3475 is a…”
Get full text

Chemotherapy resistance in breast cancer by Lehnert, M

“…Chemotherapy resistance is a major problem in the management of patients with breast cancer. Clinical resistance of solid tumors such as breast cancer is…”
Get more information

Methods to detect P-glycoprotein-associated multidrug resistance in patients tumors : Consensus recommendations by BECK, W. T, GROGAN, T. M, BROPHY, N. A, BROXTERMAN, H. J, CHAN, H. S. L, DALTON, W. S, DIETEL, M, FOJO, A. T, GASCOYNE, R. D, HEAD, D, HOUGHTON, P. J, SRIVASTAVA, D. K, WILLMAN, C. L, LEHNERT, M, LEITH, C. P, PAIETTA, E, PAVELIC, Z. P, RIMSZA, L, RONINSON, I. B, SIKIC, B. I, TWENTYMAN, P. R, WARNKE, R, WEINSTEIN, R, CORDON-CARDO, C, PARHAM, D. M, KUTTESCH, J. F, ANDREEFF, M, BATES, S. E, BERARD, C. W, BOYETT, J. M

“…Multidrug resistance (MDR), especially that associated with overexpression of MDR1 and its product, P-glycoprotein (Pgp), is thought to play a role in the…”
Get full text

Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: A randomised phase II study by Khoo, Kei Siong, Manzoor Zaidi, Syed Hasan, Srimuninnimit, Vichien, Song, Santai, Nair, Reena, Ngelangel, Corazon A., Bustam, Anita, Reece, William H.H., Lehnert, Manfred

“…The purpose was to evaluate the activity and toxicity of split-dose paclitaxel or docetaxel in combination with gemcitabine in patients with metastatic breast…”
Get full text

Reversal of P-glycoprotein-associated multidrug resistance: the challenge continues by Lehnert, M

Get more information

Foreword by Lehnert, Manfred, Gallen, St

Get full text

Multidrug resistance in cancer by LEHNERT, Manfred, TWENTYMAN, Peter

Get full text

Reversal of multidrug resistance in breast cancer: many more open questions than answers by Lehnert, M

Get more information

Multidrug-Resistant Myeloma: Laboratory and Clinical Effects of Verapamil as a Chemosensitizer by Salmon, Sydney E., Dalton, William S., Grogan, Thomas M., Plezia, Patricia, Lehnert, Manfred, Roe, Denise J., Miller, Thomas P.

“…Verapamil was evaluated as a chemosensitizer for reversing multidrug resistance in multiple myeloma both in vitro and in clinical trials. Bone marrows from 59…”
Get full text

Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer by Abratt, Raymond P, Lee, Jung Sin, Han, Ji Youn, Tsai, Chun-Ming, Boyer, Michael, Mok, Tony, Kim, Sang-We, Lee, Jin Soo, Brnabic, Alan J M, Reece, William H H, Lehnert, Manfred

“…The aim of this single-arm phase II study was to evaluate the efficacy, feasibility, and safety of the gemcitabine-carboplatin-paclitaxel combination as…”
Get more information

Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer by Pummer, K, Lehnert, M, Stettner, H, Hubmer, G

“…Hormone deprivation is the gold standard for the treatment of metastatic prostate cancer. However, prostate cancer being primarily a heterogeneous tumor…”
Get more information

P-201 First-line chemotherapy with gemzar ® (gemcitabine, GEM) and cisplatin (CIs) in Asian patients with advanced non-small cell lung cancer (NSCLC) — A prospective observational study by Kim, Sun Young, Sudershan, Gambhir, Villalon, Antonio H., Shaharyar, Shaharyar, Vu, Vu V., Park, Jae Yong, John, Subhashini, Jung, Maan-Hong, Lehnert, Manfred

Get full text

Dexverapamil: A clinical approach to circumvention of multidrug resistance by Dalton, William S., Lehnert, Manfred

Get full text